Vanguard Group
QTTB icon

Vanguard Group’s Q32 Bio QTTB Stock Holding History

Vanguard Group’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.07M Buy
321,051
+25,642
+9% +$72.5K ﹤0.01% 3763
2025
Q3 		$585K Buy
295,409
+25,980
+10% +$49.9K ﹤0.01% 3913
2025
Q2 		$401K Sell
269,429
-39,785
-13% -$67.8K ﹤0.01% 3969
2025
Q1 		$510K Sell
309,214
-7,358
-2% -$19.8K ﹤0.01% 3883
2024
Q4 		$1.09M Buy
316,572
+31,156
+11% +$984K ﹤0.01% 3733
2024
Q3 		$12.7M Buy
285,416
+147,049
+106% +$5.4M ﹤0.01% 2835
2024
Q2 		$2.48M Buy
138,367
+30,615
+28% +$733K ﹤0.01% 3490
2024
Q1 		$1.84M Sell
107,752
-3
-0% -$41 ﹤0.01% 3620
2023
Q4 		$1.18M Sell
107,755
-5,936
-5% -$86.8K ﹤0.01% 3774
2023
Q3 		$2.39M Hold
113,691
– – ﹤0.01% 3524
2023
Q2 		$1.81M Hold
113,691
– – ﹤0.01% 3696
2023
Q1 		$2.11M Hold
113,691
– – ﹤0.01% 3655
2022
Q4 		$2.58M Buy
113,691
+47
+0% +$1.25K ﹤0.01% 3573
2022
Q3 		$3.29M Buy
113,644
+6,515
+6% +$266K ﹤0.01% 3536
2022
Q2 		$3.8M Buy
107,129
+7,996
+8% +$273K ﹤0.01% 3518
2022
Q1 		$5.42M Sell
99,133
-9,463
-9% -$588K ﹤0.01% 3485
2021
Q4 		$7.12M Sell
108,596
-5,452
-5% -$529K ﹤0.01% 3418
2021
Q3 		$16.2M Sell
114,048
-3,845
-3% -$490K ﹤0.01% 2978
2021
Q2 		$15.4M Buy
117,893
+31,672
+37% +$3.95M ﹤0.01% 2976
2021
Q1 		$14.6M Buy
86,221
+1,661
+2% +$350K ﹤0.01% 2947
2020
Q4 		$17.2M Buy
84,560
+4,272
+5% +$826K ﹤0.01% 2716
2020
Q3 		$15.5M Sell
80,288
-1,309
-2% -$293K ﹤0.01% 2576
2020
Q2 		$22.3M Buy
81,597
+18,031
+28% +$4.81M ﹤0.01% 2367
2020
Q1 		$17.8M Buy
63,566
+343
+0.5% +$105K ﹤0.01% 2352
2019
Q4 		$23.6M Sell
63,223
-157
-0.2% -$45K ﹤0.01% 2455
2019
Q3 		$20.6M Buy
63,380
+6,929
+12% +$2.36M ﹤0.01% 2479
2019
Q2 		$19.9M Buy
56,451
+19,772
+54% +$7.77M ﹤0.01% 2513
2019
Q1 		$18.3M Buy
36,679
+6,119
+20% +$2.74M ﹤0.01% 2547
2018
Q4 		$12.3M Buy
30,560
+4,230
+16% +$1.6M ﹤0.01% 2669
2018
Q3 		$10.8M Buy
26,330
+194
+0.7% +$65.9K ﹤0.01% 2872
2018
Q2 		$9.6M Buy
26,136
+25,180
+2,634% +$9.01M ﹤0.01% 2920
2018
Q1 		$322K Buy
+956
New +$321K ﹤0.01% 3879

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group's QTTB Position: Q4 2025 in Review

Vanguard Group increased its Q32 Bio (QTTB) stake by 8.7% in Q4 2025, buying an estimated $72.5K and bringing the position to 321,051 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3763.

Vanguard Group first reported a position in QTTB in Q1 2018 and has held it in 32 quarters since. The position peaked at $23.6M in Q4 2019. 52 funds tracked by Wall St. Rank hold QTTB as of Q4 2025.

  • Vanguard Group held 321,051 shares of Q32 Bio worth $1.07M as of Q4 2025.
  • Vanguard Group bought 25,642 Q32 Bio shares in Q4 2025, an estimated $72.5K.
  • Q32 Bio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3763 holding.
  • Vanguard Group first reported a position in Q32 Bio in Q1 2018 and has held it in 32 quarters since.
  • Vanguard Group's Q32 Bio position peaked at $23.6M in Q4 2019.
  • 52 funds tracked by Wall St. Rank held Q32 Bio as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.